Financials Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra 16:35:04 14/06/2024 BST 5-day change 1st Jan Change
8.4 EUR +0.72% Intraday chart for Evotec SE -4.87% -60.53%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,473 4,950 7,444 2,696 3,765 1,489 - -
Enterprise Value (EV) 1 3,614 4,949 7,099 2,485 3,787 1,716 1,676 1,520
P/E ratio 92.2 x 757 x 32.7 x -15.4 x -45.3 x -53.8 x 31.7 x 24.1 x
Yield - - - - - - - -
Capitalization / Revenue 7.78 x 9.88 x 12 x 3.59 x 4.82 x 1.69 x 1.44 x 1.28 x
EV / Revenue 8.1 x 9.88 x 11.5 x 3.31 x 4.85 x 1.94 x 1.61 x 1.31 x
EV / EBITDA 29.3 x 46.4 x 66.2 x 24.4 x 57.1 x 18.1 x 8.85 x 6.18 x
EV / FCF 332 x -91.1 x 2,155 x 114 x -21.4 x -10 x 22.8 x 12.8 x
FCF Yield 0.3% -1.1% 0.05% 0.88% -4.67% -9.96% 4.39% 7.83%
Price to Book 7.25 x 6.86 x 5.44 x 2.27 x 3.37 x 1.4 x 1.32 x 1.29 x
Nbr of stocks (in thousands) 150,653 163,476 175,162 176,703 176,936 177,292 - -
Reference price 2 23.05 30.28 42.50 15.26 21.28 8.400 8.400 8.400
Announcement Date 26/03/20 25/03/21 12/04/22 12/05/23 24/04/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 446.4 500.9 618 751.4 781.4 882.6 1,038 1,159
EBITDA 1 123.1 106.6 107.3 101.7 66.35 94.61 189.4 245.8
EBIT 1 62.59 48.52 41 20.85 -26.63 -10.86 67.51 113.5
Operating Margin 14.02% 9.69% 6.63% 2.77% -3.41% -1.23% 6.51% 9.79%
Earnings before Tax (EBT) 1 56.56 25.81 237 -154 -80.59 -33.33 38.42 101.6
Net income 1 38.07 6.252 215.5 -175.7 -83.91 -28.89 31.74 78.55
Net margin 8.53% 1.25% 34.87% -23.38% -10.74% -3.27% 3.06% 6.78%
EPS 2 0.2500 0.0400 1.300 -0.9900 -0.4700 -0.1562 0.2653 0.3484
Free Cash Flow 1 10.89 -54.35 3.294 21.75 -176.9 -171 73.5 119
FCF margin 2.44% -10.85% 0.53% 2.89% -22.64% -19.38% 7.08% 10.26%
FCF Conversion (EBITDA) 8.85% - 3.07% 21.4% - - 38.8% 48.4%
FCF Conversion (Net income) 28.61% - 1.53% - - - 231.54% 151.49%
Dividend per Share 2 - - - - - - - -
Announcement Date 26/03/20 25/03/21 12/04/22 12/05/23 24/04/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 231 187.1 164.7 172.2 336.9 173.9 240.7 170.3 383.8 196.3 250.1 208.7 207.4 228 251 245.5 245.8
EBITDA 1 47.27 37.21 18.9 14.7 33.64 10.96 57.05 - 26.1 24.11 16.14 7.815 19.73 27.37 36.09 - -
EBIT 1 18.92 14.94 0.463 -3.77 -3.307 -13.53 37.69 -36.29 - -12.19 -7.687 -14.74 -4.233 2.116 10.18 - -
Operating Margin 8.19% 7.99% 0.28% -2.19% -0.98% -7.78% 15.66% -21.31% - -6.21% -3.07% -7.06% -2.04% 0.93% 4.06% - -
Earnings before Tax (EBT) 1 - -17.84 - -24.34 - -43.36 -17.52 -20.44 - -29.92 -24.02 -26.78 -2.761 5.756 13.64 - -
Net income 1 - -31.48 -73.24 -27.94 -101.2 -47.28 -27.2 -14.93 -28.83 -38.96 -16.13 -20.67 -11.7 -1.051 2.121 - -
Net margin - -16.83% -44.48% -16.22% -30.03% -27.19% -11.3% -8.77% -7.51% -19.85% -6.45% -9.9% -5.64% -0.46% 0.84% - -
EPS 2 - -0.2000 -0.4100 -0.1600 -0.5700 -0.2700 -0.1500 -0.0800 - -0.2200 -0.0900 -0.1200 -0.0400 -0.0200 0.0200 - -
Dividend per Share - - - - - - - - - - - - - - - - -
Announcement Date 12/08/20 12/04/22 11/05/22 11/08/22 11/08/22 09/11/22 12/05/23 29/08/23 29/08/23 08/11/23 24/04/24 22/05/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 141 - - - 22.1 227 187 30.7
Net Cash position 1 - 0.67 345 212 - - - -
Leverage (Debt/EBITDA) 1.149 x - - - 0.3329 x 2.399 x 0.9846 x 0.1247 x
Free Cash Flow 1 10.9 -54.4 3.29 21.8 -177 -171 73.5 119
ROE (net income / shareholders' equity) 8.45% 1.04% 20.5% -13.7% -5.46% -6.67% 4.88% 5.84%
ROA (Net income/ Total Assets) 3.89% 0.47% 11.7% -7.82% -2.8% 0.8% 1.13% 2.06%
Assets 1 978.7 1,322 1,849 2,246 3,002 -3,611 2,809 3,819
Book Value Per Share 2 3.180 4.420 7.810 6.720 6.320 6.020 6.350 6.490
Cash Flow per Share 2 0.2800 0.2900 0.7300 1.150 0.2100 0.1900 0.7600 0.9400
Capex 1 31.3 99.1 119 181 213 160 116 127
Capex / Sales 7.02% 19.78% 19.25% 24.13% 27.3% 18.16% 11.19% 10.91%
Announcement Date 26/03/20 25/03/21 12/04/22 12/05/23 24/04/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.4 EUR
Average target price
20.79 EUR
Spread / Average Target
+147.50%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW